transmembrane protein 161AGenealiases: AROS-29 · AROS29
Q-omics provides the consensus-scored TMEM161A profile across patient tissues and cancer cell-line models. TMEM161A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM161A is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TMEM161A protein abundance shows 22,071 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TMEM161A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM161A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM161A survival associations across molecular data types. TMEM161A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM161A RNA expression–survival associations across cancer types. High TMEM161A expression shows unfavorable associations in UVM, KIRP, LGG and ACC, but favorable associations in STAD and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM161A RNA expression.
This table summarizes TMEM161A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM161A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM161A shows higher tumor expression in KIRC, COAD, HNSC, KIRP, STAD and LIHC. The KIRC box plot shows higher TMEM161A RNA expression in tumor versus normal tissue (log2 FC = +0.828, t-test p < 0.001).
This table shows molecular features associated with TMEM161A in patient tissues and cancer cell lines. In patient samples, TMEM161A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM161A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
